Roche first-half results beat estimates

21 July 2016
roche-700

Swiss pharma giant Roche (ROG: SIX) this morning posted first-half 2016 financial results, reporting profit that beat analysts’ consensus estimates, but the firm’s share price was barely changed in early trading, up a modest 0.3% at 253.80 Swiss francs.

The company said net income rose 4% to 5.5 billion Swiss francs ($5.57 billion) in the six month period, exceeding forecasts of 5.3 billion francs. Core earnings per share, which exclude some items, increased 7.2% to 7.74 francs, beating the 7.65-franc estimate of nine analysts surveyed by Bloomberg.

Revenue increased 6% (+4.8% at constant exchange rates) to 25 billion francs, just ahead of a consensus forecast of 24.79 billion francs in a Reuters poll.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical